Phase 2 N=143 A Study of IVX-A12 in Adults Participants
Healthy Participants
Primary: Model-adjusted Geometric Mean Concentration (GMC) for RSV/A Neutralizing Antibodies (NAb) — 5910.4; 10500.4 internation unit per milliliter (IU/mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=53 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
Follicular Thyroid Cancer · Insular Thyroid Cancer · Papillary Thyroid Cancer
Primary: Overall Objective Response Rate, Defined as the Proportion of Patients Who Have a Minor Response (MR), Partial Response (PR), or Complete Response(CR)Assessed According…
Phase 2 N=58 To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
Advanced Solid Tumor
Primary: Safety Run-in: Number of Participants With Adverse Events (AEs) — 6; 4; 0 Participants
Phase 2 N=32 Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4; 7 Participants
Phase 2 N=20 Effect of Benralizumab in Atopic Dermatitis
Dermatitis, Atopic · Dermatitis · Eczema
Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2
Phase 2 N=286 Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
Contraception
Primary: The Primary Outcome Measure is Effectiveness as Calculated by the Pearl Index — 0.53; 1.41; 0.00 Pearl Index
Phase 2 N=35 Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma · Stage IV Pancreatic Cancer AJCC v8
Primary: Maximal Tolerated Dose (MTD) of Siltuximab That Can be Combined With Spartalizumab — 11 mg/kg
Phase 2 N=499 Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 — -20.7; -18.5; -24.0; -17.8 Score on a scale — p=0.241
Phase 2 N=116 Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
Corneal Erosion
Primary: Change From Baseline to Week 12 in Total Corneal Fluorescein Staining — -2.55; -0.37 units on a scale
Phase 2 N=129 Transcranial Direct Current Stimulation for Post-stroke Motor Recovery
Stroke, Ischemic · Motor Activity · Upper Extremity Paralysis
Primary: Mean Change in FM-UE From Baseline — 4.91; 3.87; 5.53 units on a scale — p=0.39
Phase 2 N=53 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 — -0.58; -1.03 Score on a scale — p==0.224
Phase 2 N=33 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Frontotemporal Dementia
Primary: Severity of TEAEs — 43; 58; 84; 4 TEAEs (all)
Phase 2 N=80 Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Cerebral Cavernous Malformation
Primary: Percent Change in Mean Lesional QSM (QSM Change Score) — 7.35; 0.24; 15.18; 26.80 absolute value of percent change
Phase 2 N=13 Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
Parkinson Disease · Amyotrophic Lateral Sclerosis
Primary: AMDX-2011P Adverse Events Profile — 0; 1; 3 Treatment Emergent Adverse Events TEAEs
Phase 2 N=314 A Study of Auxora in Patients With Severe COVID-19 Pneumonia
Pneumonia
Primary: Number of Days From the Start of the First Infusion of Study Drug (SFISD) to Recovery — 5; 12; 7.0; 10.0 Days